Free Trial

Surgery Partners (NASDAQ:SGRY) Shares Gap Down - Should You Sell?

Surgery Partners logo with Medical background

Surgery Partners, Inc. (NASDAQ:SGRY - Get Free Report)'s share price gapped down prior to trading on Tuesday . The stock had previously closed at $23.17, but opened at $20.01. Surgery Partners shares last traded at $20.22, with a volume of 1,462,798 shares changing hands.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SGRY. Macquarie decreased their price target on shares of Surgery Partners from $34.00 to $33.00 and set an "outperform" rating for the company in a research note on Tuesday, March 11th. Royal Bank Of Canada restated an "outperform" rating and set a $35.00 target price on shares of Surgery Partners in a research report on Tuesday, March 25th. Benchmark reaffirmed a "buy" rating and issued a $35.00 price target on shares of Surgery Partners in a report on Monday, April 21st. Finally, Barclays decreased their target price on shares of Surgery Partners from $25.00 to $24.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Surgery Partners has an average rating of "Moderate Buy" and a consensus target price of $33.56.

View Our Latest Report on SGRY

Surgery Partners Stock Performance

The firm has a market cap of $2.47 billion, a price-to-earnings ratio of -12.61 and a beta of 1.93. The firm's 50 day moving average is $22.36 and its 200-day moving average is $22.66. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.73 and a current ratio of 1.89.

Surgery Partners (NASDAQ:SGRY - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.04). Surgery Partners had a positive return on equity of 2.41% and a negative net margin of 6.10%. The company had revenue of $776.00 million during the quarter, compared to analyst estimates of $777.77 million. During the same quarter last year, the firm posted $0.10 earnings per share. The firm's revenue for the quarter was up 8.2% compared to the same quarter last year. Sell-side analysts anticipate that Surgery Partners, Inc. will post 0.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Surgery Partners

A number of hedge funds have recently bought and sold shares of the company. Bayforest Capital Ltd acquired a new stake in Surgery Partners in the 1st quarter worth $1,017,000. Woodline Partners LP acquired a new stake in shares of Surgery Partners during the first quarter worth approximately $12,478,000. Empowered Funds LLC raised its position in Surgery Partners by 11.0% in the 1st quarter. Empowered Funds LLC now owns 12,853 shares of the company's stock valued at $305,000 after purchasing an additional 1,278 shares during the last quarter. Caxton Associates LLP acquired a new position in Surgery Partners during the 1st quarter worth about $4,351,000. Finally, Twin Securities Inc. bought a new stake in shares of Surgery Partners during the first quarter valued at approximately $7,844,000.

About Surgery Partners

(Get Free Report)

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.

Further Reading

Should You Invest $1,000 in Surgery Partners Right Now?

Before you consider Surgery Partners, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surgery Partners wasn't on the list.

While Surgery Partners currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines